Sarepta Therapeutics, Inc. SRPT

Latest FY: 2025 Healthcare Biotechnology
Market Price $23.00
Market Cap $2.43B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑15.6% YoY
$2.20B
3-Yr CAGR: 37.6%
Net Income ↓-403.3% YoY
-$713.41M
Net Margin: -32.5%
Free Cash Flow ↑10.3% YoY
-$307.45M
FCF Yield: -12.66%
EPS (Diluted) ↓-404.7% YoY
$-7.13
Basic: $-7.13
Return on Equity Efficiency
-62.5%
ROA: -21.3%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (SRPT)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $5.4M $5.3M $-267.3M $-245.8M $-251.2M
FY 2017 $154.6M +2,751.6% $-49.0M $-50.7M +81.0% $-232.0M $-244.0M +2.9%
FY 2018 $301.0M +94.7% $-135.9M $-361.9M -614.0% $-388.7M $-449.8M -84.4%
FY 2019 $380.8M +26.5% $-420.8M $-715.1M -97.6% $-456.5M $-516.1M -14.7%
FY 2020 $455.9M +19.7% $-246.3M $-554.1M +22.5% $107.5M $25.3M +104.9%
FY 2021 $612.4M +34.3% $-177.1M $-418.8M +24.4% $-443.2M $-481.7M -2,006.5%
FY 2022 $843.8M +37.8% $-84.8M $-703.5M -68.0% $-8.03 $-325.3M $-356.2M +26.1%
FY 2023 $1,243.3M +47.4% $214.0M $-536.0M +23.8% $-5.80 +27.8% $-501.0M $-577.1M -62.0%
FY 2024 $1,902.0M +53.0% $776.0M $235.2M +143.9% $2.34 +140.3% $-205.8M $-342.7M +40.6%
FY 2025 $2,198.2M +15.6% $2,160.1M $-713.4M -403.3% $-7.13 -404.7% $-205.5M $-307.5M +10.3%
$

Valuation

Market Price $23.00
Market Cap $2.43B
Enterprise Value $2.46B
P/E Ratio N/A
P/B Ratio 2.13
FCF Yield -12.66%
Dividend Yield N/A
Shares Outstanding 105,576,200
%

Profitability & Margins

Gross Margin 98.26%
Operating Margin -31.83%
Net Margin -32.45%
Return on Equity (ROE) -62.55%
Return on Assets (ROA) -21.30%
Asset Turnover 0.66x
Revenue 3-Yr CAGR 37.60%
🛡️

Financial Health & Liquidity

Current Ratio 2.32
Cash Ratio 0.73
Debt / Equity 0.727
Debt / Assets 0.247
Cash & Equivalents $801.28M
Total Debt $828.97M
Book Value / Share $10.80
💧

Cash Flow Efficiency

Operating Cash Flow -$205.48M
Capital Expenditures (CapEx) $101.97M
Free Cash Flow -$307.45M
OCF / Revenue -9.35%
FCF / Revenue -13.99%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-7.13
EPS (Basic) $-7.13
Dividends / Share N/A
Book Value / Share $10.80
EPS YoY Growth -404.70%
🏛️

Balance Sheet (FY 2025)

Total Assets $3.35B
Total Liabilities $2.21B
Stockholders' Equity $1.14B
Current Assets $2.54B
Current Liabilities $1.10B